Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Expenses (2016 - 2025)

Fennec Pharmaceuticals' Operating Expenses history spans 15 years, with the latest figure at $16.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 84.34% year-over-year to $16.3 million, compared with a TTM value of $50.9 million through Dec 2025, up 13.24%, and an annual FY2025 reading of $50.9 million, up 13.24% over the prior year.
  • Operating Expenses for Q4 2025 was $16.3 million at Fennec Pharmaceuticals, up from $12.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $16.3 million in Q4 2025, with the low at -$5.0 million in Q2 2022.
  • Average Operating Expenses over 5 years is $8.3 million, with a median of $8.0 million recorded in 2023.
  • Year-over-year, Operating Expenses tumbled 227.78% in 2022 and then soared 259.53% in 2023.
  • Tracing FENC's Operating Expenses over 5 years: stood at $4.2 million in 2021, then surged by 81.74% to $7.6 million in 2022, then skyrocketed by 52.33% to $11.6 million in 2023, then decreased by 23.32% to $8.9 million in 2024, then skyrocketed by 84.34% to $16.3 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Operating Expenses are $16.3 million (Q4 2025), $12.7 million (Q3 2025), and $12.4 million (Q2 2025).